225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.

[1]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[2]  U. Haberkorn,et al.  Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. , 2016, Journal of medicinal chemistry.

[3]  R. Fimmers,et al.  Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.

[4]  E. Demirci,et al.  Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[6]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  U. Haberkorn,et al.  213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  RubiniGiuseppe,et al.  Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. , 2014 .

[9]  J. Ullmann,et al.  225Ac and 223Ra production via 800 MeV proton irradiation of natural thorium targets. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[10]  J. Ullmann,et al.  225-Ac and 223-Ra Production via 800 MeV Proton Irradiation of Natural Thorium Target , 2012, 1204.2299.

[11]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[12]  C. Apostolidis,et al.  An Improved Method for the Production of Ac‐225/Bi‐213 from Th‐229 for Targeted Alpha Therapy , 2007 .

[13]  C. Apostolidis,et al.  Production of Ac-225 from Th-229 for targeted alpha therapy. , 2005, Analytical chemistry.

[14]  C. Apostolidis,et al.  Cyclotron production of Ac-225 for targeted alpha therapy. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[15]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[16]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[17]  M. Andreeff,et al.  Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Giuseppe Rubini,et al.  Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. , 2014, Cancer biotherapy & radiopharmaceuticals.

[20]  J. Humm,et al.  Targeted alpha particle immunotherapy for myeloid leukemia. , 2002, Blood.